By: IPP Bureau
Last updated : October 06, 2024 10:01 am
The acquisition will strengthen the overall company’s position as leading global CRO services partner
Jubilant Biosys Innovative Research Services, Singapore (JBIRSPL), a subsidiary of Jubilant Biosys Limited, a wholly owned subsidiary of Jubilant Pharmova, has signed and issued a put option offer to Pierre Fabre Laboratories (PF), which sets forth an offer to acquire 80% equity capital (approx. Euro 4.4 million over a period of 2 years) in a new company to be incorporated in France, which new company shall acquire Pierre Fabre's R&D Centre (Including R&D Site and R&D activities) at Saint Julien, France.
Jasmin, a new Société par Actions Simplifiée (SAS) incorporated by Pierre Fabre group in France to operate the research and preclinical development activities with discovery capabilities in Biologics and ADCs including (without limitation) various activities up to a drug candidate selection as are being currently carried out by Pierre Fabre at the research and development centre “Institut de Recherche Pierre Fabre” located Saint-Julien-en-Genevois, France. Jasmin will also acquire land and buildings and induct approximately 40 employees of the R&D center of Pierre Fabre.
Expanding the Jubilant Biosys service offerings in emerging technologies such as Biologics (Mabs) and Antibody Drug Conjugate. Establishing an R&D presence in Europe to better serve the European market and USA customers.
The acquisition will strengthen the overall company’s position as leading global CRO services partner.